Subcutaneous & Disseminated Xenografts
Subcutaneous engraftment of hematological malignances into mice is an easy and efficient method to get access to preclinical tests, which benefits from its brief techniques as well as lower budget. Creative Animodel has established more than 40 subcutaneous xenografts of hematological malignances to support your preclinical drug efficiency tests, which involve the following species but are not limited to: acute lymphoblastic leukemia, acute monocytic leukemia, acute myeloid leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, chronic myeloid leukemia, eosinophilic leukemia, histiocytic lymphoma, megakaryoblastic leukemia, multiple myeloma and non-hodgkin lymphoma.
In combination with the models mentioned above, disseminated xenografts of the referred malignances types in Creative Animodel are also available to customers. On behalf of the scientific research, Creative Animodel is dedicated to develop up-to-date hematological tumor types to replenish our model bank which ensuring a wide variety of testing alternatives for your agents. Besides, our xenografts portfolio is evaluated on a regular basis for response to standards of care, and to make emphasize, this data is also available for designing combination studies. Additionally, hematological tumor cell lines in our cryo-bank are ready for customers to immediately develop animal models and await your further enquiry.
Fig.1 Xenograft models of hematological malignances supplied by Creative Animodel.
| XENOGRAFTS | CELLLINES | PDX |
|---|---|---|
| Acute Lymphoblastic Leukemia | MOLM-13, MOLT-4, Jurkat, E6-1,CCRF-CEM | Available |
| Acute Monocytic Leukemia | U937, THP-1 | Available |
| Acute Myeloid Leukemia | KG-1 | - |
| Acute Myeloblastic Leukemia | Kasumi-1, Kasumi-3(CD33+) | - |
| Acute Promyelocytic Leukemia | HL-60 | - |
| Chronic Myeloid Leukemia | K-562, K-562-luc | - |
| Eosinophilic Leukemia | EOL-1 | - |
| Erythro Leukemia | TF-1 | - |
| Histiocytic Lymphoma | U-937 | - |
| Megakaryoblastic Leukemia | SET-2 | - |
| Multiple Myeloma | H929, KMS-11, KMS-26, KMS-12-BM OPM-2, RPMI 8226, 8226-luc, ARH-77, ML-2 | - |
| Non-Hodgkin Lymphoma | DoHH-2, Daudi, Farage, Granta 519, JEKO-1, KARPAS-299, Namalwa, Raji, Raji-luc, Ramos, REC-1, RL, SU-DHL-1, SU-DHL-4, WSU-DLCL2 | Available |
In disseminated leukemia xenografts, luciferase-labelled hematological tumor cells are usually intravenously injected into the tail vein. Clinical symptoms associated with tumor progression include impairment of hind limb function, cachexia, ocular proptosis, weight loss etc, in alliance with bioluminescent observation, which ensures precise disease and therapeutic monitoring.
Specific research approaches include the following spectrum, but are not limited to
- • Bioluminescence imaging and data processing
- • Immunofluorescence (IF)
- • Fluorescence activated cell sorting
- • Immuno-labelling and analysis of the immune organ resided tumor cells
- • Immunohistochemistry analysis (IHC)
- • Histopathological analysis
- • Wright-Giemsa staining of the peripheral blood
Creative Animodel provides compelling service chain offered by our scientific staff to assist customers in selecting the most appropriate model for your agent candidate. Mono- or multi-therapy with the appropriate clinical agent is available. Efficacy evaluation on our hematological malignances models can be combined with:
- • Pharmacokinetic or bioavailability analysis
- • Biomarker screening and validation
